RAPT Therapeutics Announces Successful Completion of GSK Tender Offer and Merger, Shares to Delist

summarizeSummary

RAPT Therapeutics announced the successful completion of the tender offer by GSK, with the merger expected to finalize today, leading to the company's delisting.

check_boxKey Events

• Tender Offer Successfully Completed

  The tender offer by Redrose Acquisition Co., a subsidiary of GSK, for all outstanding shares of RAPT Therapeutics expired on March 2, 2026. A total of 30,137,567 shares, representing approximately 93.36% of the issued and outstanding shares, were validly tendered and not withdrawn, satisfying the minimum condition.

• Merger Expected Today

  All conditions to the offer have been satisfied, and the Purchaser has accepted all validly tendered shares for payment. The acquisition of RAPT Therapeutics through a merger is expected to be completed today, March 3, 2026, with RAPT becoming a direct wholly-owned subsidiary of GSK's parent company.

• Shares to be Delisted

  Following the consummation of the merger, RAPT Therapeutics' shares will be delisted and will cease trading on the Global Select Stock Market. Steps will also be taken to terminate the registration of the shares under the Exchange Act and suspend all reporting obligations.

auto_awesomeAnalysis

This filing marks the definitive conclusion of the tender offer by GSK's subsidiary, Redrose Acquisition Co., for RAPT Therapeutics. With over 93% of shares tendered, the minimum condition has been met, and the merger is expected to complete today, March 3, 2026. This event fundamentally alters the investment thesis for RAPT Therapeutics, as it will cease to be a publicly traded company, and shareholders who tendered their shares will receive $58.00 in cash per share. The delisting of shares from the Global Select Stock Market and termination of SEC reporting obligations will follow promptly.